Volpara Health Technologies Limited has entered into a collaboration agreement with Natera, Inc.to bring Natera's Empower Hereditary Cancer Test to Volpara's customers in the United States. Volpara will integrate Natera's Empower Hereditary Cancer Test into Volpara's software workflow to create additional access for women to comprehensive genetic testing services in different clinical settings. At least one Volpara software product is used with over 33% of women who attend screening each year in the United States.

Customers use Volpara's market-leading breast cancer risk assessment software to confidently make informed decisions for triaging patients to supplemental imaging and/or genetic testing based on their personalised risk. Risk assessment is also required by many US insurance companies before additional testing. Along with supplemental screening, such as ultrasound and MRI, genetic testing assists in earlier cancer detection and is critical in reducing treatment costs and increasing the chances of survival.